Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.25 AUD | +3.22% | -0.16% | -22.91% |
Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Commercial Products
100.0
%
| - | - | 232 | 100.0 % | - |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| - | - | 232 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 20-07-31 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-07 |
James Shaw
COO | Chief Operating Officer | - | 13-07-31 |
Larry Glass
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Gerry Zhao
PRN | Corporate Officer/Principal | - | 22-01-31 |
Nancy E. Jones
PRN | Corporate Officer/Principal | - | 13-01-08 |
Clive Blower
PRN | Corporate Officer/Principal | - | 14-08-24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 02-03-04 | |
Dianne Angus
BRD | Director/Board Member | 63 | 18-07-04 |
Jenny Lee Harry
BRD | Director/Board Member | - | 18-07-04 |
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Larry Glass
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Patrick Davies
CHM | Chairman | 57 | 18-07-04 |
Joe Basile
BRD | Director/Board Member | - | 23-03-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 129,665,676 | 108,308,667 ( 83.53 %) | 2,400,000 ( 1.851 %) | 83.53 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.75% | 1.55B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- NEU Stock
- Company Neuren Pharmaceuticals Limited